Literature DB >> 14557631

Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations.

Valery Fikkert1, Bénédicte Van Maele, Jo Vercammen, Anke Hantson, Barbara Van Remoortel, Martine Michiels, Cristina Gurnari, Christophe Pannecouque, Marc De Maeyer, Yves Engelborghs, Erik De Clercq, Zeger Debyser, Myriam Witvrouw.   

Abstract

The diketo acid L-708,906 has been reported to be a selective inhibitor of the strand transfer step of the human immunodeficiency virus type 1 (HIV-1) integration process (D. Hazuda, P. Felock, M. Witmer, A. Wolfe, K. Stillmock, J. A. Grobler, A. Espeseth, L. Gabryelski, W. Schleif, C. Blau, and M. D. Miller, Science 287:646-650, 2000). We have now studied the development of antiviral resistance to L-708,906 by growing HIV-1 strains in the presence of increasing concentrations of the compound. The mutations T66I, L74M, and S230R emerged successively in the integrase gene. The virus with three mutations (T66I L74M S230R) was 10-fold less susceptible to L-708,906, while displaying the sensitivity of the wild-type virus to inhibitors of the RT or PRO or viral entry process. Chimeric HIV-1 strains containing the mutant integrase genes displayed the same resistance profile as the in vitro-selected strains, corroborating the impact of the reported mutations on the resistance phenotype. Phenotypic cross-resistance to S-1360, a diketo analogue in clinical trials, was observed for all strains. Interestingly, the diketo acid-resistant strain remained fully sensitive to V-165, a novel integrase inhibitor (C. Pannecouque, W. Pluymers, B. Van Maele, V. Tetz, P. Cherepanov, E. De Clercq, M. Witvrouw, and Z. Debyser, Curr. Biol. 12:1169-1177, 2002). Antiviral resistance was also studied at the level of recombinant integrase. Single mutations did not appear to impair specific enzymatic activity. However, 3' processing and strand transfer activities of the recombinant integrases with two (T66I L74M) and three (T66I L74M S230R) mutations were notably lower than those of the wild-type integrase. Although the virus with three mutations was resistant to inhibition by diketo acids, the sensitivity of the corresponding enzyme to L-708,906 or S-1360 was reduced only two- to threefold. As to the replication kinetics of the selected strains, the replication fitness for all strains was lower than that of the wild-type HIV-1 strain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557631      PMCID: PMC229256          DOI: 10.1128/jvi.77.21.11459-11470.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

Review 1.  Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections.

Authors:  E De Clercq
Journal:  J Med Chem       Date:  1995-07-07       Impact factor: 7.446

2.  Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition.

Authors:  M D Miller; C M Farnet; F D Bushman
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

3.  Integration is essential for efficient gene expression of human immunodeficiency virus type 1.

Authors:  H Sakai; M Kawamura; J Sakuragi; S Sakuragi; R Shibata; A Ishimoto; N Ono; S Ueda; A Adachi
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

4.  Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase.

Authors:  W E Robinson; M Cordeiro; S Abdel-Malek; Q Jia; S A Chow; M G Reinecke; W M Mitchell
Journal:  Mol Pharmacol       Date:  1996-10       Impact factor: 4.436

5.  Mode of interaction of G-quartets with the integrase of human immunodeficiency virus type 1.

Authors:  P Cherepanov; J A Esté; R F Rando; J O Ojwang; G Reekmans; R Steinfeld; G David; E De Clercq; Z Debyser
Journal:  Mol Pharmacol       Date:  1997-11       Impact factor: 4.436

6.  Human immunodeficiency virus integration protein expressed in Escherichia coli possesses selective DNA cleaving activity.

Authors:  P A Sherman; J A Fyfe
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

7.  Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA.

Authors:  F D Bushman; R Craigie
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

8.  Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit human immunodeficiency virus replication. 2. Effect of heteroaromatic linkers on the activity of bicyclams.

Authors:  G J Bridger; R T Skerlj; S Padmanabhan; S A Martellucci; G W Henson; M J Abrams; H C Joao; M Witvrouw; K De Vreese; R Pauwels; E De Clercq
Journal:  J Med Chem       Date:  1996-01-05       Impact factor: 7.446

9.  T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1.

Authors:  J O Ojwang; R W Buckheit; Y Pommier; A Mazumder; K De Vreese; J A Esté; D Reymen; L A Pallansch; C Lackman-Smith; T L Wallace
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

10.  Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells.

Authors:  R L LaFemina; C L Schneider; H L Robbins; P L Callahan; K LeGrow; E Roth; W A Schleif; E A Emini
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

View more
  32 in total

1.  New HIV Drugs in Development, 2005.

Authors:  Jeffrey P Nadler; Michael C Phillips
Journal:  Curr Infect Dis Rep       Date:  2005-05       Impact factor: 3.725

Review 2.  Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.

Authors:  Mark A Winters; Thomas C Merigan
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

3.  Discovery of a small-molecule HIV-1 integrase inhibitor-binding site.

Authors:  Laith Q Al-Mawsawi; Valery Fikkert; Raveendra Dayam; Myriam Witvrouw; Terrence R Burke; Christoph H Borchers; Nouri Neamati
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-19       Impact factor: 11.205

4.  Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors.

Authors:  Ira B Dicker; Brian Terry; Zeyu Lin; Zhufang Li; Sagarika Bollini; Himadri K Samanta; Volodymyr Gali; Michael A Walker; Mark R Krystal
Journal:  J Biol Chem       Date:  2008-06-24       Impact factor: 5.157

5.  Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes.

Authors:  Romina Quercia; Elisabeth Dam; Danielle Perez-Bercoff; François Clavel
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

6.  Identification of amino acids in HIV-1 and avian sarcoma virus integrase subsites required for specific recognition of the long terminal repeat Ends.

Authors:  Aiping Chen; Irene T Weber; Robert W Harrison; Jonathan Leis
Journal:  J Biol Chem       Date:  2005-11-18       Impact factor: 5.157

7.  A quantum mechanic/molecular mechanic study of the wild-type and N155S mutant HIV-1 integrase complexed with diketo acid.

Authors:  Cláudio Nahum Alves; Sergio Martí; Raquel Castillo; Juan Andrés; Vicent Moliner; Iñaki Tuñón; Estanislao Silla
Journal:  Biophys J       Date:  2007-11-02       Impact factor: 4.033

Review 8.  HIV resistance to raltegravir.

Authors:  Francois Clavel
Journal:  Eur J Med Res       Date:  2009-11-24       Impact factor: 2.175

9.  Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.

Authors:  Michael E Abram; Rebecca M Hluhanich; Derrick D Goodman; Kristen N Andreatta; Nicolas A Margot; Linda Ye; Anita Niedziela-Majka; Tiffany L Barnes; Nikolai Novikov; Xiaowu Chen; Evguenia S Svarovskaia; Damian J McColl; Kirsten L White; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

Review 10.  Integrase and integration: biochemical activities of HIV-1 integrase.

Authors:  Olivier Delelis; Kevin Carayon; Ali Saïb; Eric Deprez; Jean-François Mouscadet
Journal:  Retrovirology       Date:  2008-12-17       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.